Conjugate Or Complex Of Monoclonal Or Polyclonal Antibody, Immunoglobulin, Or Fragment Thereof With Nonimmunoglobulin Material Patents (Class 424/178.1)
  • Patent number: 11028375
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: June 8, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 11020489
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: June 1, 2021
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 11001631
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 11, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Nikolai Kley, Anje Cauwels, Sarah Gerlo
  • Patent number: 10973923
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 13, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Christoph Mahlert, Anne-Sophie Rebstock, Simone Greven, Nils Griebenow, Jan Tebbe, Oliver Kensch
  • Patent number: 10974059
    Abstract: A method for the treatment of tumor(s) or tumor cell(s) or cancer(s) in a subject in need by the generation of heat. The latter is produced by chains of magnetosomes extracted from whole magnetotactic bacteria and subjected to an alternating magnetic field. These chains of magnetosomes yield efficient antitumoral activity whereas magnetosomes unbound from the chains or kept within the whole bacteria produce poor or no antitumoral activity. The introduction of various chemicals such as chelating agents and/or transition metals within the growth medium of the bacteria improves the heating properties of the chains of magnetosomes. Moreover, the insertion of the chains of magnetosomes within a lipid vesicle is also suggested in order to favor their rotation in vivo and hence to improve their heating capacity. The vesicle can contain an antitumoral agent together with the chains of magnetosomes. In this case, the agent is released within the tumors by heating the vesicle.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 13, 2021
    Assignee: NANOBACTERIE
    Inventors: Edouard Alphandery, Stephanie Faure, Imene Chebbi
  • Patent number: 10941191
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 9, 2021
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, GLIKNIK INC.
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Patent number: 10941208
    Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human MUC16 (monospecific antibodies) and antigen-binding fragments thereof. In some embodiments, the anti-MUC16 antibodies and the antigen-binding fragments thereof are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: March 9, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
  • Patent number: 10925971
    Abstract: Provided herein are methods of treating prolactin receptor positive breast cancer using an antibody drug conjugate (ADC) comprising an anti-PRLR antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent. In certain embodiments, the anti-PRLR antibody or antigen-binding fragment thereof is conjugated to maytansinoid. In certain embodiments, the method of treating PRLR positive breast cancer includes administering the ADC in combination with one or more chemotherapeutic agents.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: February 23, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Marcus Kelly, Jessica Kirshner, Gavin Thurston
  • Patent number: 10918713
    Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: February 16, 2021
    Assignee: La Jolla Institute For Allergy And Immunology
    Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
  • Patent number: 10918736
    Abstract: The present invention relates to a conjugate in which an immunoglobulin Fc region is linked to therapeutic enzymes through a non-peptide polymer linkage moiety, and more specifically, to a conjugate in which a non-peptide polymer linkage moiety is specifically linked to an immunoglobulin Fc, a method of preparing the same, and a composition comprising the same.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: February 16, 2021
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Dae Jin Kim, Jung Kuk Kim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 10906990
    Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: February 2, 2021
    Assignees: RIKEN, KYOWA KIRIN CO., LTD.
    Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
  • Patent number: 10870709
    Abstract: The present invention relates to antibodies and binding fragments thereof that bind the ?-sheet secondary structure of a pathological monomeric or oligomeric non-fibrillar proteins without binding to the non-toxic, non-pathological forms of these proteins or peptides These antibodies and binding fragments thereof are suitable for the diagnosis, prevention, and treatment of protein conformational disorders including all amyloid diseases.
    Type: Grant
    Filed: July 22, 2017
    Date of Patent: December 22, 2020
    Assignee: NEW YORK UNIVERSITY
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Patent number: 10835592
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: November 17, 2020
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
  • Patent number: 10814036
    Abstract: Methods for the ex vivo modification of the surfaces of viable tissue result in tissue modifications that are stable and/or result in the controlled release of active compounds, and are expected to provide effective protection for transplanted tissue subsequent to transplant.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 27, 2020
    Assignee: BAYLOR UNIVERSITY
    Inventors: Bob Kane, Babatope Akinbobuyi, Charles Chang, Bashoo Naziruddin
  • Patent number: 10793626
    Abstract: Subject matter of the present invention is an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold binding to the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2 for use in a therapy of cancer. Subject matter of the present invention is anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment of cancer according to claim 1 wherein said anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold requires the presence of a C-terminally amidated tyrosine residue within the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2, for binding.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 6, 2020
    Assignee: ANGIOBIOMED GMBH
    Inventor: Andreas Bergmann
  • Patent number: 10784923
    Abstract: A receiving apparatus includes: a capacitance element connected to a receiving side of a transmission line through which a transmission signal is transmitted, and where a direct current flowing through the transmission line changes in accordance with a logic level of a data signal; a transistor configured to amplify a current flowing between a receiving-side node and a power supply node to which a power supply potential is supplied, where the receiving-side node is positioned between the transmission line and the capacitance element; and a data signal generator configured to generate the data signal based on the current amplified by the transistor.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: September 22, 2020
    Assignee: YAMAHA CORPORATION
    Inventor: Mikio Kitano
  • Patent number: 10780294
    Abstract: A problem of incomplete inhibition of harmful cells/bacteria and short duration of time, after the photodynamic treatment, during which such cells may re-grow, is solved by exposing the target bacteria with a multi-component photosensitizer material formed by adding a predetermined potentiating chemical to a conventional single-component photosensitizer at the target, prior to irradiating the target with light. The multi-component photosensitizer is effectuated by forming a mix of the two chemical compositions or by sequential exposure of the bacteria to a single-component photosensitizer and the potentiating chemical of choice.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 22, 2020
    Assignee: The General Hospital Corporation
    Inventors: Daniela Vecchio, Michael R. Hamblin, Yingying Huang, Liyi Huang, Giacomo Landi, Jeffrey Gelfand, Timothy Brauns
  • Patent number: 10768174
    Abstract: Methods are disclosed for tethering a biological entity to a substrate comprising: (a) forming a supported lipid bilayer on a surface of a substrate, wherein the supported lipid bilayer comprises an anchor molecule conjugated to a first affinity tag that is present in the lipid bilayer at a concentration greater than or equal to 5 mole percent; and (b) contacting the supported lipid bilayer with a biological entity, wherein the biological entity comprises an nonlinear-active label and a second affinity tag capable of binding to the first affinity tag, thereby tethering the biological entity to the supported lipid bilayer in an oriented fashion.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 8, 2020
    Assignee: BLUELIGHT THERAPEUTICS, INC.
    Inventor: Joshua Salafsky
  • Patent number: 10758628
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-substituted heteroaryl compounds used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates and compounds, as well as methods of using the same.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 1, 2020
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Stepan Chuprakov, Romas Alvydas Kudirka, Jesse M. McFarland, Albert W. Garafalo, David Rabuka
  • Patent number: 10751358
    Abstract: Multitargeted pyrimidine nucleoside carbamates, substituted with fluorine at both the base and the sugar moieties, are disclosed (see Formula I): where R=linear or branched alkyl (C1-7); R?=H, hydroxy protecting group; R?=H, phosphate ester, amino acid alkyl (C1-7) ester phoshoramidate, or phosphorodiamidate. The disclosed compounds are fluoropyrimidine prodrugs that are characterized by a novel combination of structural components that provide intracellular metabolites capable of 1) inhibiting several cellular enzymes required for the synthesis and proper functioning of DNA, and 2) causing DNA damage by misincorporation into DNA. By acting on multiple targets with different mechanisms of action, compounds of Formula I reduce the likelihood of the emergence of drug resistance, a major drawback of the use of nucleoside-based anticancer and antiviral drugs.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 25, 2020
    Inventor: Thomas I. Kalman
  • Patent number: 10738124
    Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: August 11, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Joel H. Martin, Frank Delfino, Thomas Nittoli, Marcus Kelly
  • Patent number: 10717781
    Abstract: The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: July 21, 2020
    Assignees: National Cancer Center, Chugai Seiyako Kabushiki Kaisha
    Inventors: Shuichi Mitsunaga, Atsushi Ochiai
  • Patent number: 10689458
    Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 23, 2020
    Assignee: Pfizer Inc.
    Inventors: Dangshe Ma, Frank Loganzo, Jr., Kimberly Ann Marquette, Edmund Idris Graziani, Puja Sapra, Pavel Strop
  • Patent number: 10686670
    Abstract: A computer-implemented method includes: receiving, by a computing device, information regarding a range in which an Internet-of-Things (IoT) network is to be implemented; determining, by the computing device, respective detection scores for a plurality of IoT devices for each of a plurality of proposed congregation of IoT devices; determining, by the computing device, a minimum number of the plurality of IoT devices to cover the range by incorporating the detection scores into a covariance model; and outputting, by the computing device, information identifying the minimum number of the plurality of IoT devices for designing the IoT network.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 16, 2020
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Abhay Patra, Harish Bharti, Rajesh Kumar Saxena
  • Patent number: 10676732
    Abstract: The present invention relates to a method for producing a lysine carboxylase mutant strain, characteristics of the mutant strain, a gene encoding the lysine decarboxylase mutant strain, and a method for producing cadaverine using the same. The present invention provides lysine decarboxylase derived from E. coli improved through a protein engineering variation. In addition, the lysine decarboxylase mutant strain of the present invention increases activity, pH stability, and thermal stability at the time of producing cadaverine, thereby reducing production costs, through increasing a yield and productivity.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: June 9, 2020
    Assignee: Seoul National University R&DB Foundation
    Inventors: Byung Gee Kim, Eun Young Hong
  • Patent number: 10656167
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: May 19, 2020
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
  • Patent number: 10654904
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 19, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10626187
    Abstract: Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Kite Pharma, Inc.
    Inventors: Jed Wiltzius, Stuart Sievers
  • Patent number: 10613081
    Abstract: A kit and method for evaluation of the quality and the operating parameters of any types of fully automated open ELISA instruments are disclosed. The kit and method can be used to reliably assess quality control parameters including precision, volume removal accuracy, plate reader accuracy, plate reader linearity, plate washer quality, drift absence, and carryover absence. The evaluation can be completed in a timely and cost-effective manner and provide laboratories with the ability to readily validate the operation and performance of a fully automated ELISA instrument.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: April 7, 2020
    Inventors: Alireza Palangi, Samira Bayat Bidkorpeh
  • Patent number: 10610587
    Abstract: This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: April 7, 2020
    Assignee: CELLTRION INC.
    Inventors: Shin Jae Chang, Soo Young Lee, Byung Pil Lim, Pan Kyeom Kim, Sang Tae Park, Jung Sun Ahn, Eun Bee Park, Sun Ju Keum, Man Ki Song, Jung Ah Choi
  • Patent number: 10604580
    Abstract: The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 31, 2020
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Henk M. Lokhorst, Tuna Mutis, Inger S Nijhof, Niels Van de Donk
  • Patent number: 10603389
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: March 31, 2020
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • Patent number: 10603338
    Abstract: A method is provided for the poly signal activation of apoptosis of malignant solid tumour cells, carried out by means of the targeted delivery of thallium salts by surface-modified MS2 phage virions, which contain a cyclic iRGD ligand that has a high affinity for the integrins avb3 and avb5 and is covalently bound with the shell and with the core, which contains genomic RNA and thallium salts. Complex, efficient, prolonged cytotoxic action is provided on focal and metastatic clusters of malignant solid tumour cells, while minimizing undesirable side effects on the healthy cells of an organism.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: March 31, 2020
    Assignee: OBSHESTVO S ORGANICHENNOI OTVETSTVENNOST'YU “BIOTEHNOLOGIYA”
    Inventors: Tat'yana Nikolaevna Bol'shakova, Ekaterina Feodorovna Kolesanova, Ekaterina Ur'evna Rybalkina, Igor′ Gennad'evich Sivov
  • Patent number: 10597433
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: March 24, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10588972
    Abstract: The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye® 700DX.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 17, 2020
    Assignee: LI-COR, INC.
    Inventor: Joy L. Kovar
  • Patent number: 10577429
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 3, 2020
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 10537644
    Abstract: The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: January 21, 2020
    Assignee: RC BIOTECHNOLOGIES, INC.
    Inventors: Chang Jiang Huang, Jianmin Fang, Hui Ye, Lezhi Zhang
  • Patent number: 10533059
    Abstract: The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: January 14, 2020
    Assignee: AKAMARA THERAPEUTICS, INC.
    Inventors: Shiladitya Sengupta, Monideepa Roy, Nimish Gupta, Seikh Samad Hossain
  • Patent number: 10517969
    Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: December 31, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Neil H. Bander, Joseph Osborne, Stanley J. Goldsmith, Shankar Vallabhajosula
  • Patent number: 10519218
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 31, 2019
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Patent number: 10513545
    Abstract: The present invention relates to: a fusion polypeptide in which an anti-inflammatory polypeptide and a ferritin monomer fragment are bound; and a pharmaceutical composition for treating inflammatory diseases, containing the same as an active ingredient and, more specifically, to: a fusion polypeptide in which an anti-inflammatory polypeptide is fused to an N-terminus and/or a C-terminus of a ferritin monomer fragment from which a portion of a fourth loop and a fifth helix, of a human derived ferritin monomer, are removed; and a use thereof for treating inflammatory diseases.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: December 24, 2019
    Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jong-Sup Bae, In-San Kim, Won Hwa Lee, Jun Young Seo, So Youn Kim
  • Patent number: 10513541
    Abstract: Disclosed are a mutated HPV11 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV11 and HPV6), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also disclosed is use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: December 24, 2019
    Assignees: Xiamen University, Xiamen Innovax Biotech Co., Ltd.
    Inventors: Shaowei Li, Daning Wang, Xinlin Liu, Zhihai Li, Jun Zhang, Ningshao Xia
  • Patent number: 10508131
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 17, 2019
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Patent number: 10502746
    Abstract: One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of a) providing the sample to be analyzed, b) incubating said serum or plasma sample with an antibody that specifically binds to rat IgG and that does not specifically bind to mouse IgG, wherein the antibody is i) a mixture of an antibody binding to rat kappa light chain and an antibody binding to rat lambda light chain, or ii) a mixture of an antibody binding to rat IgG1 with an avidity of 4.1×1010 M?1 or more, an antibody binding to rat IgG2a with an avidity of 8.6×109 M?1 or more, an antibody binding to rat IgG2b with an avidity of 6.4×1010 M?1 or more and an antibody binding to rat IgG2c with an avidity of 9.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: December 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Uwe Wessels
  • Patent number: 10485868
    Abstract: The present invention develops a vaccine composition against and treatment or prevention on inflammation and lung injury (particularly hyperoxia-induced lung injury) and progression of periodontitis. Tn immunization increases serum anti-Tn antibody titers, while it decreases lavaged protein and cytokines, and also decreases mean linear intercept and lung injury score. Furthermore, the improvement in lung injury is accompanied by a decrease in NF-?B activity.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: November 26, 2019
    Assignee: TAIPEI MEDICAL UNIVERSITY
    Inventors: Jaulang Hwang, Chung-Ming Chen
  • Patent number: 10485881
    Abstract: Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: November 26, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Michelle S. Bradbury, Barney Yoo, Ulrich Wiesner, Kai Ma
  • Patent number: 10463750
    Abstract: This disclosure describes compositions and methods for selectively recruiting antigen-specific T cells and re-direct them to kill targeted cells, particularly tumor cells. This approach permits selective engagement of specific effector cell populations and, by using nanoparticles, overcomes the geometric limitations associated with previous approaches.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: November 5, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Christian Schuetz
  • Patent number: 10457719
    Abstract: In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: October 29, 2019
    Assignee: The Jackson Laboratory
    Inventors: Derry Roopenian, Gregory Christianson
  • Patent number: 10428131
    Abstract: The disclosure provides GITRL fusion polypeptide subunits comprising an IgG Fc domain, a trimerization domain, and the receptor binding domain of GITR ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 1, 2019
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ross Anthony Stewart, Natalie Jo Tigue, Lesley Lynn Young, Daniel Ramsay Higazi, Lisa Bamber, Sudharsan Sridharan, Rebecca Leyland, Nicholas Mason Durham
  • Patent number: 10383932
    Abstract: A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the ?-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to ?-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 20, 2019
    Assignee: MicroVAX, LLC
    Inventor: Albert B. Deisseroth